Clinical Use Of Cb1 Antagonists Sr 141716

The selective CB1 antagonist SR 141716 (rimonabant or Acomplia; Sanofi-Synthelabo), when administered to marijuana smokers, caused weight loss in overweight and obese subjects without causing adverse side effects (118). Based on this and the promising studies on animals (reviewed previously), SR 141716 has been used in randomized, double-blind clinical trials to determine its efficacy in treating obesity and related metabolic complications. Several Phase III clinical trials named RIO (Rimonabant In Obesity) were initiated starting in 2001 and included more than 6600 overweight or obese patients with or without comorbidities who were given SR141716 (5 or 20 mg) or placebo for up to 2 yr (119 - 121). All subjects were on a calorie-restricted diet and underwent a run-in period of diet alone prior to being randomized to drug or placebo conditions.

Quick Weight Loss Action

Quick Weight Loss Action

Why Indulge In Self-Pity When You Can Do Something About Your Weight Now. Say Goodbye to Your Weight Problems That Have Only Make Your Life Nothing But Miserable. Have you often felt short-changed because of your weight or physical appearance?

Get My Free Ebook


Post a comment